|
Cosmo Pharmaceuticals N.V. (0RGI.L) DCF Valuation |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
Cosmo Pharmaceuticals N.V. (0RGI.L) Bundle
Streamline your analysis and improve precision with our (0RGIL) DCF Calculator! Utilizing actual data from Cosmo Pharmaceuticals N.V. and customizable assumptions, this tool enables you to forecast, analyze, and value Cosmo Pharmaceuticals like a seasoned investor.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 57.4 | 61.2 | 96.1 | 87.3 | 251.1 | 348.1 | 482.6 | 669.0 | 927.4 | 1,285.7 |
| Revenue Growth, % | 0.00 | 6.77 | 56.88 | -9.12 | 187.55 | 38.63 | 38.63 | 38.63 | 38.63 | 38.63 |
| EBITDA | 7.4 | 38.1 | 44.7 | 18.5 | 156.0 | 142.7 | 197.8 | 274.2 | 380.2 | 527.0 |
| EBITDA, % | 12.86 | 62.21 | 46.52 | 21.23 | 62.11 | 40.99 | 40.99 | 40.99 | 40.99 | 40.99 |
| Depreciation | 5.7 | 6.9 | 13.0 | 12.8 | 11.6 | 37.6 | 52.1 | 72.3 | 100.2 | 138.9 |
| Depreciation, % | 9.90 | 11.32 | 13.57 | 14.61 | 4.60 | 10.80 | 10.80 | 10.80 | 10.80 | 10.80 |
| EBIT | 1.7 | 31.2 | 31.7 | 5.8 | 144.4 | 105.1 | 145.7 | 202.0 | 280.0 | 388.1 |
| EBIT, % | 2.96 | 50.89 | 32.94 | 6.62 | 57.51 | 30.19 | 30.19 | 30.19 | 30.19 | 30.19 |
| Total Cash | 200.3 | 209.1 | 226.8 | 47.3 | 134.6 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 25.4 | 23.0 | 36.3 | 26.8 | 17.8 | 109.6 | 152.0 | 210.7 | 292.0 | 404.9 |
| Account Receivables, % | 44.28 | 37.57 | 37.82 | 30.67 | 7.10 | 31.49 | 31.49 | 31.49 | 31.49 | 31.49 |
| Inventories | 5.4 | 12.3 | 10.8 | 13.4 | 12.7 | 42.6 | 59.0 | 81.8 | 113.4 | 157.2 |
| Inventories, % | 9.36 | 20.16 | 11.26 | 15.30 | 5.06 | 12.23 | 12.23 | 12.23 | 12.23 | 12.23 |
| Accounts Payable | 2.5 | 3.9 | 7.1 | 8.3 | 8.6 | 21.5 | 29.8 | 41.3 | 57.3 | 79.5 |
| Accounts Payable, % | 4.30 | 6.30 | 7.43 | 9.47 | 3.41 | 6.18 | 6.18 | 6.18 | 6.18 | 6.18 |
| Capital Expenditure | -7.6 | -8.0 | -6.9 | -14.4 | -5.3 | -36.3 | -50.3 | -69.7 | -96.6 | -134.0 |
| Capital Expenditure, % | -13.27 | -13.07 | -7.16 | -16.50 | -2.12 | -10.42 | -10.42 | -10.42 | -10.42 | -10.42 |
| Tax Rate, % | -11.76 | 9.94 | 29.65 | 420.69 | 13.16 | 92.33 | 92.33 | 92.33 | 92.33 | 92.33 |
| EBITAT | 1.9 | 28.1 | 22.3 | -18.6 | 125.4 | 8.1 | 11.2 | 15.5 | 21.5 | 29.8 |
| Depreciation | 5.7 | 6.9 | 13.0 | 12.8 | 11.6 | 37.6 | 52.1 | 72.3 | 100.2 | 138.9 |
| Changes in Account Receivables | -91.8 | -42.4 | -58.7 | -81.3 | -112.9 | |||||
| Changes in Inventories | -29.9 | -16.4 | -22.8 | -31.6 | -43.8 | |||||
| Changes in Accounts Payable | 12.9 | 8.3 | 11.5 | 16.0 | 22.2 | |||||
| Capital Expenditure | -7.6 | -8.0 | -6.9 | -14.4 | -5.3 | -36.3 | -50.3 | -69.7 | -96.6 | -134.0 |
| UFCF | -28.3 | 23.9 | 19.9 | -12.1 | 141.6 | -99.4 | -37.4 | -51.9 | -72.0 | -99.9 |
| WACC, % | 10.36 | 10.36 | 10.36 | 10.35 | 10.36 | 10.36 | 10.36 | 10.36 | 10.36 | 10.36 |
| PV UFCF | -90.1 | -30.7 | -38.6 | -48.5 | -61.0 | |||||
| SUM PV UFCF | -269.0 | |||||||||
| Long Term Growth Rate, % | 3.50 | |||||||||
| Free cash flow (T + 1) | -103.4 | |||||||||
| Terminal Value | -1,507.2 | |||||||||
| Present Terminal Value | -920.7 | |||||||||
| Enterprise Value | -1,189.6 | |||||||||
| Net Debt | -40.0 | |||||||||
| Equity Value | -1,149.6 | |||||||||
| Diluted Shares Outstanding, MM | 16.0 | |||||||||
| Equity Value Per Share | -71.85 |
Benefits You Will Receive
- Pre-Filled Financial Model: Actual data from Cosmo Pharmaceuticals N.V. (0RGIL) facilitates accurate DCF valuation.
- Comprehensive Forecast Control: Modify revenue growth, profit margins, WACC, and other essential factors.
- Real-Time Calculations: Automatic updates provide immediate results as you adjust inputs.
- Professional-Grade Template: A polished Excel file crafted for high-quality valuation presentations.
- Flexible and Reusable: Designed for adaptability, allowing multiple uses for in-depth forecasting.
Highlights of Cosmo Pharmaceuticals N.V. (0RGIL)
- Comprehensive Financial Data: Gain access to reliable pre-loaded historical performance and future forecasts.
- Adjustable Forecast Parameters: Modify highlighted cells for metrics such as WACC, growth rates, and profit margins.
- Real-Time Calculations: Benefit from automatic updates for DCF, Net Present Value (NPV), and cash flow assessments.
- User-Friendly Dashboard: Utilize clear charts and summaries to effectively interpret your valuation findings.
- Designed for All Levels: A straightforward and intuitive layout catering to investors, CFOs, and advisors alike.
How It Functions
- 1. Access the Template: Download and open the Excel spreadsheet containing Cosmo Pharmaceuticals N.V.'s (0RGIL) preloaded data.
- 2. Modify Key Inputs: Adjust essential parameters such as growth rates, WACC, and capital expenditures.
- 3. Observe Instant Results: The DCF model automatically computes the intrinsic value and NPV in real time.
- 4. Explore Different Scenarios: Analyze various forecasts to evaluate alternative valuation results.
- 5. Present with Assurance: Deliver professional valuation analyses to bolster your decision-making process.
Why Opt for the Cosmo Pharmaceuticals N.V. (0RGIL) Calculator?
- Precision: Utilizes authentic Cosmo Pharmaceuticals financials for reliable data.
- Adaptability: Built to allow users to experiment and adjust inputs with ease.
- Efficiency: Eliminate the need to construct a DCF model from the ground up.
- High-Quality Standards: Crafted with the expertise and usability expected at the CFO level.
- Intuitive Interface: Simple to navigate, even for individuals with limited financial modeling skills.
Who Should Utilize This Product?
- Investors: Accurately estimate Cosmo Pharmaceuticals N.V.’s (0RGIL) fair value before making investment decisions.
- CFOs: Utilize a professional-grade DCF model for financial reporting and analysis related to Cosmo Pharmaceuticals N.V. (0RGIL).
- Consultants: Efficiently customize the template for valuation reports for clients involving Cosmo Pharmaceuticals N.V. (0RGIL).
- Entrepreneurs: Acquire insights into the financial modeling practices employed by leading companies in the pharmaceutical sector, including Cosmo Pharmaceuticals N.V. (0RGIL).
- Educators: Implement it as a teaching resource to illustrate various valuation methodologies applicable to Cosmo Pharmaceuticals N.V. (0RGIL).
What the Template Contains
- Historical Data: Includes Cosmo Pharmaceuticals’ past financials and baseline forecasts.
- DCF and Levered DCF Models: Comprehensive templates for calculating Cosmo Pharmaceuticals' intrinsic value.
- WACC Sheet: Pre-designed calculations for Weighted Average Cost of Capital.
- Editable Inputs: Customize key drivers such as growth rates, EBITDA %, and CAPEX assumptions.
- Quarterly and Annual Statements: A thorough breakdown of Cosmo Pharmaceuticals’ financials.
- Interactive Dashboard: Dynamically visualize valuation results and projections.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.